Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation

F1000Research
E W Petersdorf

Abstract

Graft-versus-host disease (GVHD) remains a significant potentially life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). Since the discovery of the human leukocyte antigen (HLA) system over 50 years ago, significant advances have clarified the nature of HLA variation between transplant recipients and donors as a chief etiology of GVHD. New information on coding and non-coding gene variation and GVHD risk provides clinicians with options to consider selected mismatched donors when matched donors are not available. These advances have increased the availability of unrelated donors for patients in need of a transplant and have lowered the overall morbidity and mortality of HCT.

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D E GeraghtyD D Chaplin
Jan 1, 1990·Annual Review of Biochemistry·P J Bjorkman, P Parham
Dec 27, 1990·The New England Journal of Medicine·K FleischhauerS Y Yang
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·W J StorkusP Cresswell
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·S BahramT Spies
Feb 1, 1996·Current Opinion in Immunology·E Goulmy
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·V GrohT Spies
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·N Rouas-FreissE D Carosella
Apr 12, 2001·British Journal of Haematology·E W PetersdorfJ A Hansen
Dec 26, 2001·The New England Journal of Medicine·E W PetersdorfC Anasetti
Feb 7, 2002·Proceedings of the National Academy of Sciences of the United States of America·Vannary TiengAntoine Toubert
Nov 16, 2002·Blood·Alois GratwohlUNKNOWN Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT)
Dec 21, 2002·Immunological Reviews·Derry RoopenianAaron Brown
May 13, 2003·Nature Immunology·Daniel D BilladeauPaul J Leibson
Jun 21, 1958·Nature·J J VAN ROODA VAN LEEUWEN
Jan 1, 1964·Cold Spring Harbor Symposia on Quantitative Biology·R PAYNEJ BODMER
Jan 9, 2004·Advances in Immunology·Edgardo D CarosellaNathalie Rouas-Freiss
Apr 23, 2004·Proceedings of the National Academy of Sciences of the United States of America·Joël LeMaoultEdgardo D Carosella
May 14, 2004·Genome Research·C Andrew StewartStephan Beck
Jul 15, 2004·Blood·Effie W PetersdorfJohn A Hansen
Nov 18, 2004·Tissue Antigens·P TripathiS Agrawal
Apr 20, 2005·Placenta·R H McIntire, J S Hunt
Oct 21, 2005·Human Molecular Genetics·Zheng TanCarole Ober
Oct 29, 2005·Nature·UNKNOWN International HapMap Consortium
Dec 7, 2005·Current Topics in Microbiology and Immunology·M Carrington, M P Martin
Apr 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Zhen GuoEffie W Petersdorf
Mar 24, 2007·PLoS Medicine·Effie W PetersdorfZhen Guo

❮ Previous
Next ❯

Citations

Jul 3, 2018·HLA : Immune Response Genetics·R A Fabreti-OliveiraE Nascimento
Feb 7, 2019·Nature Reviews. Cancer·Peter A JonesDaniel D De Carvalho
Apr 7, 2018·Blood·Sophie Paczesny
Mar 18, 2020·Frontiers in Pharmacology·Patompong SatapornpongChonlaphat Sukasem
Jan 11, 2019·Frontiers in Immunology·Sandeep KumarXuefang Cao
Oct 7, 2020·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Alexander MichelsChristian J Buchholz
Feb 11, 2021·International Journal of Immunogenetics·Ann-Margaret LittlePaul A Wright
May 4, 2021·Frontiers in Immunology·Jenny Chung Yee HoJanette Siu Yin Kwok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.